PUT/NOVO-NORDISK B/1500/0.1/20.09.24 | Real-time BOERSE MUENCHEN 05:55:43 05/06/2024 pm IST | ||
| 7.56 EUR | -0.79% |
|
| Current month | -0.78% | ||
| 1 month | -13.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 7.56 | -0.79% |
| 04/24/04 | 7.62 | -1.55% |
| 03/24/03 | 7.74 | +0.78% |
| 31/24/31 | 7.68 | -1.54% |
| 30/24/30 | 7.8 | -1.64% |
Real-time BOERSE MUENCHEN
Last update June 05, 2024 at 05:55 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GQ4V3W |
| ISIN | DE000GQ4V3W6 |
| Date issued | 13/09/2023 |
| Strike | 1,500 kr |
| Maturity | 20/09/2024 (107 Days) |
| Parity | 10 : 1 |
| Emission price | 10.96 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.8 € |
|---|---|
| Lowest since issue | 7.52 € |
| Spread | 0.05 € |
| Spread % | 0.66% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
936.2
DKK
Average target price
920
DKK
Spread / Average Target
-1.73%
- Stock Market
- Warrants
- Warrant
